Table 2. PFS and disease progression rate in high-risk progression and low-risk progression group.
| Parameter | Discovery cohort | Internal validation cohort | External validation cohort | Mutation validation cohort | |||||||||||
| High-risk progression | Low-risk progression | Total | High-risk progression | Low-risk progression | Total | High-risk progression | Low-risk progression | Total | High-risk progression | Low-risk progression | Total | ||||
| PFS, progression-free survival; IQR, interquartile range. | |||||||||||||||
| No. of patients
[n (%)] |
133
(83.6) |
26
(16.4) |
159 | 123
(78.8) |
33
(21.2) |
156 | 60
(74.1) |
21
(25.9) |
81 | 51
(79.7) |
13
(20.3) |
64 | |||
| 1-year PFS
[median (IQR)] (month) |
5.1
(3.4, 7.0) |
14.3
(11.8, 20.2) |
5.7
(3.5, 8.0) |
4.8
(3.2, 6.8) |
10.1
(6.5, 16.9) |
5.5
(3.3, 7.9) |
6.2
(2.6, 8.6) |
13.9
(6.9, 23.0) |
6.0
(3.5, 8.8) |
5.2
(2.8, 8.0) |
10.0
(5.4, 15.3) |
6.0
(3.5, 8.8) |
|||
| No. of progression patients [n (%)] | |||||||||||||||
| At 10 months | 117
(88.0) |
12
(46.2) |
129
(81.1) |
95
(77.2) |
15
(45.5) |
110
(70.5) |
46
(76.7) |
8
(38.1) |
54
(66.7) |
41
(80.4) |
6
(46.2) |
47
(73.4) |
|||
| At 1 year | 120
(90.2) |
25
(96.2) |
145
(91.2) |
103
(83.7) |
25
(75.8) |
128
(82.1) |
55
(91.7) |
20
(95.2) |
75
(92.6) |
45
(88.2) |
11
(84.6) |
56
(87.5) |
|||